Fox Trial Finder

Last updated

The Fox Trial Finder is a website which facilitates Parkinson's disease clinical research by matching research participants in the United States to clinical trials. The Michael J. Fox Foundation hosts the service.

One of the motivations for establishing the platform was a lack of other suitable options for patients to seek and find clinical trials to join. [1] ClinicalTrials.gov is somewhat of an option as it does provide information on all clinical trials. [1] In practice, the Michael J. Fox Foundation felt that its research participants needed a similar service but more customized for their needs. [1] The platform was established in 2012 at a time when such a service was new and other research organizations were establishing similar services. [2] A 2014 paper described the Fox Trial Finder as being part of a broader trend for researchers to support patient communities in organizing themselves to participate in trials. [3]

The Michael J. Fox foundation does a range of other social experiments and interventions which interrelate to the platform and have the overall intent to make for better engagement between clinical trials and research participants. [4] The platform has experimented with conducting research participant study visits through remote video chat. [5] [6] In coordination with the platform, the platform has connected research participants with transportation to study sites. [7]

A 2015 evaluation found that the Fox Trial Finder was able to operate as intended and actually match research participants to trials. [8]

Related Research Articles

<span class="mw-page-title-main">Inosine</span> Chemical compound

Inosine is a nucleoside that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N9-glycosidic bond. It was discovered in 1965 in analysis of RNA transferase. Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.

<span class="mw-page-title-main">Clinical trial</span> Phase of clinical research in medicine

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted.

<span class="mw-page-title-main">Idebenone</span> Chemical compound

Idebenone is a drug that was initially developed by Takeda Pharmaceutical Company for the treatment of Alzheimer's disease and other cognitive defects. This has been met with limited success. The Swiss company Santhera Pharmaceuticals has started to investigate it for the treatment of neuromuscular diseases. In 2010, early clinical trials for the treatment of Friedreich's ataxia and Duchenne muscular dystrophy have been completed. As of December 2013 the drug is not approved for these indications in North America or Europe. It is approved by the European Medicines Agency (EMA) for use in Leber's hereditary optic neuropathy (LHON) and was designated an orphan drug in 2007.

Impulse-control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity – failure to resist a temptation, an urge, or an impulse; or having the inability to not speak on a thought. Many psychiatric disorders feature impulsivity, including substance-related disorders, behavioral addictions, attention deficit hyperactivity disorder, autism spectrum disorder, fetal alcohol spectrum disorders, antisocial personality disorder, borderline personality disorder, conduct disorder and some mood disorders.

In the management of Parkinson's disease, due to the chronic nature of Parkinson's disease (PD), a broad-based program is needed that includes patient and family education, support-group services, general wellness maintenance, exercise, and nutrition. At present, no cure for the disease is known, but medications or surgery can provide relief from the symptoms.

<span class="mw-page-title-main">Nilotinib</span> Chemical compound

Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has the Philadelphia chromosome. It may be used both in initial cases of chronic phase CML as well as in accelerated and chronic phase CML that has not responded to imatinib. It is taken by mouth.

<span class="mw-page-title-main">The Michael J. Fox Foundation</span> Parkinsons disease charity

The Michael J. Fox Foundation for Parkinson's Research aims to find a cure for Parkinson's disease (PD) founded in 2000 by Michael J. Fox. It concentrates on funding research and ensuring the development of improved therapies for people with Parkinson's.

MPP<sup>+</sup> Chemical compound

MPP+ (1-methyl-4-phenylpyridinium) is a positively charged organic molecule with the chemical formula C12H12N+. It is a neurotoxin that acts by interfering with oxidative phosphorylation in mitochondria by inhibiting complex I, leading to the depletion of ATP and eventual cell death.

<span class="mw-page-title-main">Parkinson's disease</span> Long-term degenerative neurological disorder

Parkinson's disease (PD), or simply Parkinson's, is a chronic degenerative disorder of the central nervous system that affects both the motor system and non-motor systems. The symptoms usually emerge slowly, and as the disease worsens, non-motor symptoms become more common. Early symptoms are tremor, rigidity, slowness of movement, and difficulty with walking. Problems may also arise with cognition, behaviour, sleep, and sensory systems. Parkinson's disease dementia becomes common in advanced stages of the disease.

<span class="mw-page-title-main">Befiradol</span> Chemical compound

Befiradol is an experimental drug being studied for the treatment of levodopa-induced dyskinesia. It is a potent and selective 5-HT1A receptor full agonist.

Pridopidine is an orally administrated small molecule investigational drug. Pridopidine is a selective and potent Sigma-1 Receptor agonist. It is being developed by Prilenia Therapeutics and is currently in late-stage clinical development for Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS).

Parkinson's disease clinical research is any study intended to help answer questions about etiology, diagnostic approaches or new treatments by studying their effects on human subjects. Clinical trials are designed and conducted by scientists and medical experts, who invite participants to undergo testing new vaccines, therapies, or treatments.

Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multisite study that aims to improve clinical trials for the prevention and treatment of Alzheimer's disease (AD). This cooperative study combines expertise and funding from the private and public sector to study subjects with AD, as well as those who may develop AD and controls with no signs of cognitive impairment. Researchers at 63 sites in the US and Canada track the progression of AD in the human brain with neuroimaging, biochemical, and genetic biological markers. This knowledge helps to find better clinical trials for the prevention and treatment of AD. ADNI has made a global impact, firstly by developing a set of standardized protocols to allow the comparison of results from multiple centers, and secondly by its data-sharing policy which makes available all at the data without embargo to qualified researchers worldwide. To date, over 1000 scientific publications have used ADNI data. A number of other initiatives related to AD and other diseases have been designed and implemented using ADNI as a model. ADNI has been running since 2004 and is currently funded until 2021.

David Charles is an American neurologist, professor and vice-chair of neurology, and the medical director of Telehealth at Vanderbilt University Medical Center.

<span class="mw-page-title-main">Neurolixis</span>

Neurolixis is a biopharmaceutical company focused on novel drugs for the treatment of human central nervous system diseases.

<span class="mw-page-title-main">Jonathan Sackner-Bernstein</span> American physician (born 1961)

Jonathan Sackner-Bernstein is an American physician. He has published around 80 scientific articles, which have been cited more than 4,000 times. His research has ranged from cardiac care to the efficacy of drugs. His research led to increased scrutiny of Nesiritide, a widely marketed drug, which led to its decline in its use.

<span class="mw-page-title-main">Anders Björklund</span> Swedish histologist (born 1945)

Anders Björklund' is a Swedish neuroscientist and pioneer in the study of cell- and gene-based reparative and neuroprotective mechanisms in the brain. He has spent his academic career at Lund University in Sweden, as professor since 1983 and as senior professor at the Wallenberg Neuroscience Center since his formal retirement in 2012.

<span class="mw-page-title-main">Mevidalen</span> Chemical compound

Mevidalen (developmental code name LY-3154207) is a dopaminergic drug which is under development for the treatment of Lewy body disease, including those with Parkinson's disease. It acts as a selective positive allosteric modulator (PAM) of the dopamine D1 receptor. The drug is orally active and crosses the blood–brain barrier. It is a tetrahydroisoquinoline and is a close analogue of DETQ, another D1 receptor PAM. Mevidalen has been found to have wakefulness-promoting effects in sleep-deprived humans. Side effects of mevidalen have been reported to include increased heart rate and blood pressure, insomnia, dizziness, nausea, vomiting, anxiety, nervousness, fatigue, headaches, palpitations, and contact dermatitis, as well as falls in those with dementia. As of March 2022, mevidalen is in phase 2 clinical trials for the treatment of Lewy body disease. Besides for movement disorders and dementia, D1 receptor PAMs like mevidalen might have value in the treatment of certain neuropsychiatric disorders, such as depression, excessive somnolence, and attention deficit hyperactivity disorder.

Michael S. Okun is an American neurologist, neuroscientist and author. He is the co-founder and director of the Norman Fixel Institute for Neurological Diseases at University of Florida Health and is also the chair of the Department of Neurology at the University of Florida and the Medical Director/Advisor for the Parkinson's Foundation.

A disease-modifying treatment, disease-modifying drug, or disease-modifying therapy is a treatment that delays or slows the progression of a disease by targeting its underlying cause. They are distinguished from symptomatic treatments that treat the symptoms of a disease but do not address its underlying cause.

References

  1. 1 2 3 Heger, Monica (June 2012). "Clinical trial website struggles to serve as research data hub". Nature Medicine. 18 (6): 837. doi: 10.1038/nm0612-837 . PMID   22673976.
  2. ↑ Opar, Alisa (July 2013). "New tools automatically match patients with clinical trials". Nature Medicine. 19 (7): 793. doi:10.1038/nm0713-793. PMID   23836201. S2CID   205380922.
  3. ↑ Wicks, Paul (December 2014). "Could digital patient communities be the launch pad for patient-centric trial design?". Trials. 15 (1): 172. doi: 10.1186/1745-6215-15-172 . PMC   4039333 . PMID   24885434.
  4. ↑ Chowdhury, Sohini; Meunier, Claire C; Cappelletti, Lily; Sherer, Todd B (February 2014). "Improving patient participation in Parkinson's clinical trials: the experience of the Michael J Fox Foundation". Clinical Investigation. 4 (2): 185–192. doi:10.4155/CLI.13.127.
  5. ↑ Tarolli, Christopher G.; Zimmerman, Grace A.; Goldenthal, Steven; Feldman, Blake; Berk, Sarah; Siddiqi, Bernadette; Kopil, Catherine M.; Chowdhury, Sohini; Biglan, Kevin M.; Dorsey, E. Ray; Adams, Jamie L. (February 2020). "Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants". Neurology: Clinical Practice. 10 (1): 7–14. doi:10.1212/CPJ.0000000000000680. PMC   7057071 . PMID   32190415.
  6. ↑ Dorsey, E. Ray; Wagner, Joseph D.; Bull, Michael T.; Rizzieri, Ashley; Grischkan, Justin; Achey, Meredith A.; Sherer, Todd; Chowdhury, Sohini; Meunier, Claire; Cappelletti, Lily; Rocker, Charlotte; Richard, Irene H.; Schwarz, Heidi; Kang, Gail; Ahmad, Stacy H.; Biemiller, Rachel A.; Biglan, Kevin M. (14 September 2015). "Feasibility of Virtual Research Visits in Fox Trial Finder". Journal of Parkinson's Disease. 5 (3): 505–515. doi: 10.3233/JPD-150549 . PMC   4923707 . PMID   26406130.
  7. ↑ Frank, Samuel; Berk, Sarah; Hernandez, Laura; Hogarth, Penelope; Shill, Holly A.; Siddiqi, Bernadette; Simon, David K. (December 2019). "Transportation innovation to aid Parkinson disease trial recruitment". Contemporary Clinical Trials Communications. 16: 100449. doi: 10.1016/j.conctc.2019.100449 . PMC   6804741 . PMID   31650070.
  8. ↑ Rocker, Charlotte; Cappelletti, Lily; Marshall, Claudia; Meunier, Claire C.; Brooks, Deborah W.; Sherer, Todd; Chowdhury, Sohini (2015). "Use of an Online Portal to Facilitate Clinical Trial Recruitment: A Preliminary Analysis of Fox Trial Finder". Journal of Parkinson's Disease. 5 (1): 55–66. doi: 10.3233/JPD-140522 . PMID   25624422.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.